141 related articles for article (PubMed ID: 27926611)
1. Enhanced anticancer activity of drug nanoparticles formulated with β-cyclodextrin.
Zhan H; Jagtiani T; Liang JF
Anticancer Drugs; 2017 Mar; 28(3):271-280. PubMed ID: 27926611
[TBL] [Abstract][Full Text] [Related]
2. Preparation and anticancer activity evaluation of an amorphous drug nanocomposite by simple heat treatment.
Zhan H; Liang JF
Anticancer Drugs; 2017 Jul; 28(6):623-633. PubMed ID: 28368904
[TBL] [Abstract][Full Text] [Related]
3. Lytic peptide-grafted beta-cyclodextrin polymer based nano-scaled drug delivery system with enhanced camptothecin anti-cancer efficacy.
Zhan H; Zhao H; Muhammad N; Li T; Liu Y; Wang J
Nanotechnology; 2020 Feb; 31(7):075101. PubMed ID: 31665708
[TBL] [Abstract][Full Text] [Related]
4. Camptothecin-Polysaccharide Co-assembly and Its Controlled Release.
Yang Y; Zhang YM; Li D; Sun HL; Fan HX; Liu Y
Bioconjug Chem; 2016 Dec; 27(12):2834-2838. PubMed ID: 27998070
[TBL] [Abstract][Full Text] [Related]
5. A new targeted delivery approach by functionalizing drug nanocrystals through polydopamine coating.
Zhan H; Jagtiani T; Liang JF
Eur J Pharm Biopharm; 2017 May; 114():221-229. PubMed ID: 28161549
[TBL] [Abstract][Full Text] [Related]
6. Cyclodextrin nanoparticle bound oral camptothecin for colorectal cancer: Formulation development and optimization.
Ünal S; Aktaş Y; Benito JM; Bilensoy E
Int J Pharm; 2020 Jun; 584():119468. PubMed ID: 32470483
[TBL] [Abstract][Full Text] [Related]
7. Core-crosslinked nanomicelles based on crosslinkable prodrug and surfactants for reduction responsive delivery of camptothecin and improved anticancer efficacy.
He W; Du Y; Zhou W; Wang T; Li M; Li X
Eur J Pharm Sci; 2020 Jul; 150():105340. PubMed ID: 32371069
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery.
Cirpanli Y; Bilensoy E; Lale Doğan A; Caliş S
Eur J Pharm Biopharm; 2009 Sep; 73(1):82-9. PubMed ID: 19442723
[TBL] [Abstract][Full Text] [Related]
9. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model.
Cırpanlı Y; Allard E; Passirani C; Bilensoy E; Lemaire L; Calış S; Benoit JP
Int J Pharm; 2011 Jan; 403(1-2):201-6. PubMed ID: 20951783
[TBL] [Abstract][Full Text] [Related]
10. CPT loaded nanoparticles based on beta-cyclodextrin-grafted poly(ethylene glycol)/poly (L-glutamic acid) diblock copolymer and their inclusion complexes with CPT.
Du F; Meng H; Xu K; Xu Y; Luo P; Luo Y; Lu W; Huang J; Liu S; Yu J
Colloids Surf B Biointerfaces; 2014 Jan; 113():230-6. PubMed ID: 24096159
[TBL] [Abstract][Full Text] [Related]
11. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
12. Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells.
Minelli R; Cavalli R; Ellis L; Pettazzoni P; Trotta F; Ciamporcero E; Barrera G; Fantozzi R; Dianzani C; Pili R
Eur J Pharm Sci; 2012 Nov; 47(4):686-94. PubMed ID: 22917641
[TBL] [Abstract][Full Text] [Related]
13. Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent.
Kang J; Kumar V; Yang D; Chowdhury PR; Hohl RJ
Eur J Pharm Sci; 2002 Mar; 15(2):163-70. PubMed ID: 11849913
[TBL] [Abstract][Full Text] [Related]
14. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
[TBL] [Abstract][Full Text] [Related]
15. Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe
Krishnan P; Rajan M; Kumari S; Sakinah S; Priya SP; Amira F; Danjuma L; Pooi Ling M; Fakurazi S; Arulselvan P; Higuchi A; Arumugam R; Alarfaj AA; Munusamy MA; Hamat RA; Benelli G; Murugan K; Kumar SS
Sci Rep; 2017 Sep; 7(1):10962. PubMed ID: 28887536
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic Acid-Coated Camptothecin Nanocrystals for Targeted Drug Delivery to Enhance Anticancer Efficacy.
Wang J; Muhammad N; Li T; Wang H; Liu Y; Liu B; Zhan H
Mol Pharm; 2020 Jul; 17(7):2411-2425. PubMed ID: 32437163
[TBL] [Abstract][Full Text] [Related]
17. Nanocarrier improves the bioavailability, stability and antitumor activity of camptothecin.
Tang XJ; Han M; Yang B; Shen YQ; He ZG; Xu DH; Gao JQ
Int J Pharm; 2014 Dec; 477(1-2):536-45. PubMed ID: 25445532
[TBL] [Abstract][Full Text] [Related]
18. In Vitro and In Vivo Therapeutic Evaluation of Camptothecin-Encapsulated β-Cyclodextrin Nanosponges in Prostate Cancer.
Gigliotti CL; Minelli R; Cavalli R; Occhipinti S; Barrera G; Pizzimenti S; Cappellano G; Boggio E; Conti L; Fantozzi R; Giovarelli M; Trotta F; Dianzani U; Dianzani C
J Biomed Nanotechnol; 2016 Jan; 12(1):114-27. PubMed ID: 27301177
[TBL] [Abstract][Full Text] [Related]
19. Loading studies of the anticancer drug camptothecin into dual stimuli-sensitive nanoparticles. Stability scrutiny.
Iglesias N; Galbis E; Díaz-Blanco MJ; de-Paz MV; Galbis JA
Int J Pharm; 2018 Oct; 550(1-2):429-438. PubMed ID: 30196142
[TBL] [Abstract][Full Text] [Related]
20. Development of polymeric and cyclodextrin nanoparticles for camptothecin delivery.
Cirpanli Y; Bilensoy E; Dogan AL; Calis S
J Control Release; 2010 Nov; 148(1):e21-3. PubMed ID: 21529600
[No Abstract] [Full Text] [Related]
[Next] [New Search]
